Özet:

Allogeneic hematopoietic stem cell transplantation (allo-HCT) has been extensively investigated as a potentially curative treatment option for hematological malignancies and other cancers. The current study aimed to investigate the long-term survival outcomes after allo-HCT. We retrospectively analyzed the long-term survival outcomes of patients who received allo-HCT from April 2015 to March 2021 at the Department of Haematology, SMS Hospital for different malignancies. Data from 51 patients with a mean age of 18.7 ±10.79 years who underwent peripheral blood allo-HCT as their first transplant were included for analysis. The average follow-up period was 30 months with a mortality rate of 23.52% (n=12). Overall, 39 patients were still alive and complete response was observed in 36 (92.3%) of patients. In summary, this retrospective study evidenced that peripheral blood (PB) derived allo-HCT has some survival advantages and can be successfully performed with the appropriate conditioning regimen and graft versus host disease (GVHD) prophylaxis.

Anahtar Kelimeler: